Cargando…
Risdiplam for spinal muscular atrophy
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
NPS MedicineWise
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427635/ https://www.ncbi.nlm.nih.gov/pubmed/36110169 http://dx.doi.org/10.18773/austprescr.2022.041 |
Ejemplares similares
-
Onasemnogene abeparvovec for spinal muscular atrophy
Publicado: (2022) -
Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy
por: Sergott, Robert C., et al.
Publicado: (2020) -
An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy
por: Kwon, Jennifer M., et al.
Publicado: (2022) -
Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany
por: Hahn, Andreas, et al.
Publicado: (2022) -
Correction to: Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany
por: Hahn, Andreas, et al.
Publicado: (2022)